Skip to main content
AMGN
NASDAQ Life Sciences

Amgen Beats Q3, Lifts Guidance as Three Trials Hit Endpoints

Tom Rudovsky · Reported by Wiseek News
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$477.402
Mkt Cap
$258.682B
52W Low
$294.48
52W High
$482.48
52W Position info
62% above low
Off High info
1.1% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

AMGN sits 62% above its 52-week low of $294.48.

Summary

Amgen delivered a clean Q3: revenue of $10.37 billion, up 8%, and adjusted EPS of $6.45, up 14% and ahead of forecasts, and management raised full-year revenue and adjusted EPS guidance. The quarter came with clinical wins — TEZSPIRE hit its Phase 3 endpoints in eosinophilic esophagitis, dazodalibep met its primary endpoint in Sjögren's disease, and an IMDELLTRA combination improved survival. That combination of a beat, a raise and pipeline validation is what traders pay for, and it lands with the stock near its 52-week high of $482.48. The 10-Q filed Nov. 3 already showed the $10,365 million revenue and $7.08 diluted EPS, with biosimilar erosion in Prolia and XGEVA offset by Repatha and newer products; today's release adds the adjusted numbers, the guidance raise and the trial readouts. Ten firms lifted price targets, ranging from $410 to $536, though ratings were left unchanged. The open question is obesity: RBC said it needs more MariTide data, not expected until 2027, before judging that program.

At the time of this announcement, AMGN was trading at $477.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $258.7B. The 52-week trading range was $294.48 to $482.48. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Wiseek News.


Price Chart

Share this article

Copied!

AMGN - Latest Insights

AMGN
Nov 03, 2026, 6:37 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $464.92
Real-time Price: $438.88 info
Change: -$26.04 (-6%) info
Market Cap: $236B info
AMGN
Nov 03, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $463.00
Real-time Price: $438.88 info
Change: -$24.12 (-5%) info
Market Cap: $236B info
AMGN
Nov 03, 2026, 4:01 PM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $460.57
Real-time Price: $438.88 info
Change: -$21.69 (-5%) info
Market Cap: $236B info
AMGN
Oct 26, 2026, 9:23 AM EDT
Source: Benzinga
Importance Score:
7
Price at Filing: $448.79
Real-time Price: $438.88 info
Change: -$9.91 (-2%) info
Market Cap: $236B info
AMGN
Oct 24, 2026, 10:30 AM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $439.26
Real-time Price: $438.88 info
Change: -$0.380 (-0.09%) info
Market Cap: $236B info